The Muscular Dystrophy Association (MDA) operates as a leading voluntary health organization, dedicated to the advancement of research, care, and advocacy for individuals grappling with neuromuscular diseases. The organization directly funds scientific discoveries, pioneers innovative care delivery models, including a network of multidisciplinary care centers, and supports the development of new therapies across a broad spectrum of conditions. Their strategic approach combines rigorous scientific inquiry with practical patient support mechanisms.

Founded in 1950 by Paul Cohen, a New York business leader living with facioscapulohumeral muscular dystrophy (FSHD), the MDA originated from a profound personal insight. Cohen recognized the critical absence of research and treatment options for muscular dystrophy, gathering a group with shared experiences to initiate fundraising efforts and support early scientific investigation, thereby laying the groundwork for a comprehensive medical and advocacy organization.

The MDA serves individuals and families affected by over 300 distinct neuromuscular conditions, providing them with essential resources and support. Its overarching mission is to empower the people it serves, enabling them to live longer, more independent lives. The organization strives to achieve this vision by continually driving momentum in neuromuscular research, expanding access to life-saving therapies, and advocating for policies that champion the dignity and well-being of the neuromuscular disease community.